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Abstract
Background: The NV1020 oncolytic herpes simplex virus type-1 has shown significant promise
for the treatment of many different types of tumors in experimental animal models and human
trials. Previously, we described the construction and use of the NV1020-like virus OncSyn to treat
human breast tumors implanted in nude mice. The syncytial mutation gKsyn1 (Ala-to-Val at
position 40) was introduced into the OncSyn viral genome cloned into a bacterial artificial
chromosome using double-red mutagenesis in E. coli to produce the OncdSyn virus carrying
syncytial mutations in both gB(syn3) and gK(syn1).
Results:  The OncdSyn virus caused extensive virus-induced cell fusion in cell culture. The
oncolytic potential of the OncSyn and OncdSyn viruses was tested in the highly metastatic
syngeneic mouse model system, which utilizes 4T1 murine mammary cancer cells implanted within
the interscapular region of Balb/c mice. Mice were given three consecutive intratumor injections
of OncSyn, OncdSyn, or phosphate buffered saline four days apart. Both OncSyn and OncdSyn
virus injections resulted in significant reduction of tumor sizes (p < 0.05) compared to control
tumors. Virus treated mice but not controls showed a marked reduction of metastatic foci in lungs
and internal organs. Mouse weights were not significantly impacted by any treatment during the
course of the entire study (p = 0.296).
Conclusion: These results show that the attenuated, but highly fusogenic OncSyn and OncdSyn
viruses can effectively reduce primary and metastatic breast tumors in immuncompetent mice. The
available bac-cloned OncSyn and OncdSyn viral genomes can be rapidly modified to express a
number of different anti-tumor and immunomodulatory genes that can further enhance their anti-
tumor potency.
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Background
Recent advances in molecular virology have enabled
investigators to construct viruses that selectively destroy
cancer cells (oncolytic virotherapy). Genetically engi-
neered viruses belonging to different viral families have
been evaluated for their potential as therapeutic agents in
the treatment of malignant tumors [1-4]. Efficient replica-
tion, cell lysis and spread of HSV, and their natural broad
host range make them attractive candidates as oncolytic
viral agents [5-7]. Furthermore, the recent availability of
cloned HSV genomes into bacterial artificial chromosome
vectors greatly facilitates the rapid construction of new
recombinant viruses carrying multiple transgenes of inter-
est [8-10]. Tumor treatment with oncolytic HSV has been
shown to induce anti-tumor immune responses [11-15].
Although the majority of people are seropositive for HSV-
1, oncolytic virotherapy with HSV is not limited by pre-
existing anti-HSV immunity [16,17], and in at least one
example, preexisting immunity to HSV-1 enhanced anti-
tumor immune responses [18].
Recently, the NV1020 oncolytic herpes simplex virus type-
1(HSV-1) was shown to have significant promise for the
treatment of many different types of tumors in preclinical
studies in experimental animals as well as in human clin-
ical trials [17,19-22]. The main advantage of this virus
over other HSV oncolytic viruses is that it expresses one of
the two original γ134.5 genes allowing the virus to repli-
cate more efficiently, while safety is not compromised
[23-26]. The γ134.5 gene is a major neurovirulence gene
and an inhibitor of cellular apoptosis. Deletion of this
gene drastically attenuates the virus and restricts viral
growth to cancer cells because of their lack of intact apop-
totic mechanisms [27,28]. Preclinical studies in mice as
well as phase I/II human trials have revealed that onco-
lytic HSV-1 viruses having both γ134.5 genes deleted did
not spread efficiently within tumors [29]. In contrast,
deletion of one of the two γ134.5 genes drastically attenu-
ated the virus, while allowing improved virus replication
and spread in tumor cells [23-25]. The NV1020 was orig-
inally constructed for vaccine purposes and it contains
HSV-2 viral sequences coding for glycoproteins gD, gG, gI
and gE to facilitate production of anti-HSV-2 immune
responses [24].
HSV can be transmitted from cell-to-cell by causing lim-
ited amounts of virus-induced cell fusion, thus avoiding
the extracellular environment. Specific mutations within
viral glycoproteins are known to greatly enhance virus-
induced cell fusion. Specifically, syncytial mutations that
cause extensive virus-induced cell fusion can arise in at
least two of the glycoprotein genes: the UL27 gene, encod-
ing glycoprotein B (gB) [30-32], and the UL53 gene, cod-
ing for glycoprotein K (gK) [33,34]. Work in our
laboratory has shown that gK functions as a heterodimer
with the UL20 viral protein and the UL20/gK heterodimer
is necessary for virus-induced cell fusion [35,36].
The HSV-1 oncolytic virus Onc was constructed based on
the NV1020 genomic arrangement with the exception that
there are no genomic re-arrangements and no HSV-2
genes inserted within the viral genome. Recently, we
reported that the OncSyn virus carrying a syncytial muta-
tion in gB, enabling the virus to spread among cells by
virus-induced cell fusion, replicated efficiently in breast
cancer cells in vitro and drastically reduced tumor volumes
in vivo [37]. In this study we constructed and tested the
OncdSyn virus, which in addition to the gBsyn3 mutation
also carried the gKsyn1 mutation known to enable the
virus to fuse even difficult to fuse cells [38]. Intra-tumor
injections of either virus effectively reduced tumor vol-
umes as well as inhibited tumor metastases to internal
organs.
Results
Construction and characterization of the Oncolytic HSV-1 
mutant virus OncdSyn
Previously, we described the construction and use of the
NV1020-like virus OncSyn to treat human breast cancer
utilizing a nude mouse xenograft model [37]. To further
increase the ability of the OncSyn virus to cause virus-
induced cell fusion, the syncytial mutation gKsyn1 (Ala-
to-Val at position 40) known to cause virus-induced cell
fusion of even hard to fuse cells [38] was introduced into
the OncSyn viral genome cloned into a bacterial artificial
chromosome (bac) using the markerless double-red
mutagenesis method [39]. The resultant OncdSyn virus
carried syncytial mutations in both gB (syn3) and gK
(syn1) (Fig. 1). As we reported previously for the OncSyn
virus, the bac-cloned OncdSyn viral genome was sub-
jected to PCR-diagnostic analysis and direct sequencing of
specific genomic loci to confirm the presence of the syn3
and syn1 mutations and the previously engineered dele-
tion/insertion at the γ1 34.5 locus (not shown, Materials
and Methods).
Phenotypic characteristics of the OncSyn and OncdSyn 
viruses on Vero and 4T1 cells
The plaque morphology of the HSV-1(F), OncSyn and
OncdSyn viruses was examined on Vero cells and 4T1 can-
cer cells (Balb/c spontaneous mammary adenocarcinoma-
derived) [40] as described in Materials and Methods (Fig.
2). Plaque morphologies were visualized on Vero and
4T1cells at 48 hours post infection (hpi) by immunohis-
tochemistry using a polyclonal anti-HSV-1 antibody (Fig.
2a–f). Mouse cells are known to be resistant to HSV-1
infection [41,42]. Consequently, viral plaques generated
by all three viruses tested were substantially smaller on
4T1 mouse cancer cells (Fig. 2d, e, f) in comparison to
Vero cells (Fig. 2a, b, c). Specifically, the HSV-1(F) wild-Virology Journal 2008, 5:68 http://www.virologyj.com/content/5/1/68
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type virus, which does not cause extensive virus-induced
cell fusion, produced viral plaques on 4T1 cells that were
approximately 10-fold smaller than those produced on
Vero cells (Fig. 2d and 2a). In contrast, the OncSyn and
OncdSyn viruses produced syncytial plaques on both cell
lines tested (Fig. 2b, c, e, f); however, both the OncSyn
and OncdSyn viral plaques on 4T1 cells were larger than
those produced by the HSV-1(F) wild-type virus (Fig. 2e
and 2f compared to d). The OncdSyn virus appeared to
cause more pronounced virus-induced cell fusion on both
Vero and 4T1 cells (Fig. 2c and 2f). In addition, the
OncdSyn viral plaques emitted strong red fluorescence
due to constitutive expression of the red fluorescence pro-
tein (RFP) expressed under the elongation factor 1α (EF-
1α) promoter control (Fig. 2g and 2h), as it was previ-
ously reported for the OncSyn virus [37].
Kinetics of viral replication on Vero and 4T1 cells
HSV-1(F) and OncSyn viruses replicated to similar titers
in Vero cells, while the OncdSyn virus consistently repli-
cated to titers that were a half-log lower than either HSV-
1(F), or OncSyn viruses. The kinetics of viral replication
were substantially slower in 4T1 cells than in Vero cells,
and final titers in 4T1 cells were more than two logs lower
for HSV-1(F) and OncSyn, while OncdSyn viral titers were
more than three logs lower on 4T1 cells than in Vero cells.
In addition, OncdSyn viral titers were approximately one
log lower than the HSV-1(F) and OncSyn viral titers on
4T1 cells (Fig. 3).
Intra-tumor virotherapy
4T1 cells were injected subcutaneously in the interscapu-
lar regions of Balb/c female mice. When the palpable
tumors reached the volume of approximately 80–90
mm3, mice were injected with three consecutive intra-
tumor injections of OncSyn and OncdSyn viruses or PBS
(control) every four days as described in Materials and
Methods. At the onset of viral intratumor injections,
tumor sizes appeared similar in size for all three groups of
mice (p > 0.05). Intratumor treatment with either OncSyn
or OncdSyn virus caused a substantial reduction of tumor
volumes in comparison to the PBS-treated control group
of mice (p < 0.05). There was no significant difference in
the reduction of tumor sizes in the two viral groups when
compared to each other (p > 0.05) (Fig. 4a). Analysis of
mouse weights during the course of the study did not
show significant differences among the three groups, thus
the efficacy of treatments was not affected by differential
Schematic representation of the genomic structures of the oncolytic recombinant viruses OncSyn and OncdSyn Figure 1
Schematic representation of the genomic structures of the oncolytic recombinant viruses OncSyn and 
OncdSyn. (a) Representation of the prototypic arrangement of the HSV-1 genome with the unique long (UL) and unique 
short (US) regions flanked by the terminal repeat (TR) and internal repeat (IR) regions. (b) Approximate locations of the gB 
and gK genes. (c) An expansion of the inverted repeat region showing the approximate locations of UL54, UL55, UL56, α 0, 
γ134.5, α 4, α 22 and US2 genes. (d) Schematic of the DNA fragment cloned into plasmid pJM-R, which was used for insertion 
of the HcRed gene cassette into the viral genome in place of the NV1020 genomic deletion as described in Materials and Meth-
ods.Virology Journal 2008, 5:68 http://www.virologyj.com/content/5/1/68
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weight gain/loss in the groups (not shown) (p = 0.296).
Representative tumors were excised immediately after
mice were sacrificed. Typically, tumors treated with the
PBS control injections appeared substantially larger than
those treated with either the OncSyn or OncdSyn viruses
(Fig. 4b).
The metastatic potential of the primary 4T1 tumor to
internal organs after oncolytic or control therapy was
assessed by gross and microscopic pathological examina-
tion of internal organs. In the first experimental protocol
described above, mouse tumors were allowed to grow to
approximately 80–90 mm3 and mice were sacrificed at 42
days post tumor cell implantation. In this experiment,
mouse lungs from all three groups of mice (PBS, OncSyn,
OncdSyn) had numerous metastatic foci, which were too
numerous to be accurately counted (not shown). How-
ever, tumor foci in liver and spleen were substantially
reduced in OncSyn and OncdSyn-treated mice in compar-
ison to PBS-treated control mice (Table 1, Fig. 5). Specifi-
cally, all mice in the PBS group had metastatic nodes in
liver, spleen, or kidneys. Some of the mice had tumors in
all three organs (Fig. 5). Importantly, there were no meta-
static tumors observed in the kidneys of virus-treated mice
(Table 1).
To better assess the potential of oncolytic virotherapy to
reduce metastatic tumors in internal organs, a second
experiment was performed in a similar fashion to the pre-
vious one with the exception that in the new experiment
tumors were allowed to grow to approximately 35–40
mm3 in volume and mice were sacrificed at day 33 post
tumor cell implantation after treatment with either
OncdSyn or PBS. Lungs of OncdSyn-treated mice
appeared to be practically devoid of metastatic tumors
with only two mice having two nodes each. In contrast, all
PBS-treated mice had multiple metastatic tumors in their
lungs (Table 2, Fig. 6a and 6b). These results were con-
firmed by pathological examination of paraffin-embed-
ded lung sections stained with Hematoxylin & Eosin
(H&E) staining, which revealed the absence of tumors in
OncdSyn samples, while PBS-treated control samples had
numerous visible tumor foci (Fig. 6c–f).
Discussion
The oncolytic HSV-1-based virus NV1020 has shown
strong promise for treatment of different tumors in ani-
mal models and human clinical trials [17,19-22]. To facil-
Plaque morphology of the HSV-1 (F), OncSyn and OncdSyn  viruses Figure 2
Plaque morphology of the HSV-1 (F), OncSyn and 
OncdSyn viruses. Nearly confluent Vero (a-c) and 4T1 (d-
f) cell monolayers were infected with wild-type HSV-1(F) (a, 
d), OncSyn (b, e) and OncdSyn (c, f) viruses. Individual viral 
plaques were visualized 48 hr post infection by immunohisto-
chemistry and photographed with a phase contrast micro-
scope. Vero (g) and 4T1 (h) cells were infected with 
OncdSyn virus. Viral plaques were photographed 48 hr 
postinfection with a fluorescent microscope.
Comparative kinetics of viral replication of wild-type HSV- 1(F) and mutant viruses OncSyn and OncdSyn grown on  Vero and 4T1 cells Figure 3
Comparative kinetics of viral replication of wild-type 
HSV-1(F) and mutant viruses OncSyn and OncdSyn 
grown on Vero and 4T1 cells. Near confluent monolay-
ers of Vero (a) and 4T1 (b) cells were infected at an MOI of 2 
with each virus, incubated at 37°C and the numbers of infec-
tious virions were determined at different times post infec-
tion. Viral titers (mean pfu at each time point) are shown in 
logarithmic scale. The error bars represent means ± 2 stand-
ard errors.Virology Journal 2008, 5:68 http://www.virologyj.com/content/5/1/68
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itate the construction of recombinant viruses carrying
multiple transgenes of interest, we cloned the NV1020-
like HSV-1 recombinant virus OncSyn into a bacterial arti-
ficial chromosome (bac) vector. The OncSyn virus speci-
fies a syncytial mutation in gB (Arg-to-His change at aa
858) that increases its ability to spread in tumor cells via
virus-induced cell fusion [37]. In this study, we intro-
duced the syncytial mutation syn1 (Ala-to-Val change at
aa 40) within the gK gene to further enhance the
fusogenicity of the new virus OncdSyn. The OncdSyn
virus reduced primary tumor sizes and inhibited metas-
tases to distal organs in the 4T1 syngeneic mouse model
system.
The syn1 mutation within gK has been shown to produce
extensive virus-induced cell fusion in all cells tested. In
comparison, the gBsyn3 mutation produced virus-
induced cell fusion in most cells, but it was unable to fuse
certain hard to fuse cells, such as Hep-2 cells derived from
human laryngeal carcinoma [38]. Therefore, to further
increase the ability of the OncSyn virus to fuse all types of
cells, we generated the OncdSyn virus carrying both the
gBsyn3 and gKsyn1 mutations. As expected, the OncdSyn
virus caused extensive virus-induced cell fusion and fused
Hep-2 cells, while the OncSyn virus did not (not shown).
Furthermore, the OncdSyn virus caused more extensive
fusion than OncSyn in both Vero and 4T1 cells. The
OncdSyn virus appeared to produce intact syncytia that
remained attached to the cell culture flasks, while the
OncSyn virus-induced syncytia contained infected single
cells, which detached easier than the OncdSyn-infected
syncytia. This phenomenon has been previously observed
for the gB and gK syncytial mutations and it is probably
due, in part, to the extensive virus-induced cell fusion
caused by the gK syncytial mutation, which appears to
also fuse internal membranes such as nuclear membranes
in addition to plasma membranes of cells (Kousoulas,
unpublished). Viral titers of the OncdSyn virus were lower
in Vero cells than titers of the OncSyn virus and substan-
tially lower than titers of the OncSyn virus in 4T1 cells.
Typically, HSV-1 syncytial mutants produce lower viral tit-
ers than their parental wild-type viruses, most likely
because of their direct effect on cellular membranes. In
this regard, the increased ability of the OncdSyn virus to
cause extensive virus-induced cell fusion is probably
responsible for the observed decrease in viral titers in
comparison to the OncSyn virus.
Defects of viral replication and spread in mouse cancer
cells have been described in the literature for oncolytic
herpesviruses [11,14]. HSV-1 does not replicate efficiently
in mouse cell lines [41,42] most likely because it cannot
as efficiently utilize the mouse nectin-1 receptor, which is
approximately 5% different in its amino acid sequence to
Intra-tumor treatment with OncSyn and OncdSyn viruses Figure 4
Intra-tumor treatment with OncSyn and OncdSyn 
viruses. (a) Balb/c mice were implanted subcutaneously in 
the interscapular area with 1 × 105 viable 4T1 cells. Tumors 
were measured using a digital caliper at defined time intervals 
prior and after treatment (x axis). Tumors were injected 
with either OncSyn, OncdSyn viruses, or PBS when tumors 
reached approximately 80–90 mm3 in volume. Tumor vol-
umes were measured prior to (negative values on the x axis) 
and after the injections. "0" on X axis represents the day of 
the first injection. The tumor volumes were determined 
from the formula: volume = (length × width × height)/2. 
Arrows indicate the days when therapy was administered. 
The error bars represent means ± 2 standard errors. (b) 
Tumors were excised at 42 days post implantation and visu-
ally examined. Panel shows representative tumors from virus 
and PBS treated animals.
Gross pathological examination of metastatic tumor nodules  on internal organs Figure 5
Gross pathological examination of metastatic tumor 
nodules on internal organs. Liver lobe, spleen, and kidney 
from a PBS-treated mouse carrying metastatic tumors 
(arrows) evaluated by gross pathological examination. Panel 
shows internal organs derived from a representative PBS-
treated mouse.Virology Journal 2008, 5:68 http://www.virologyj.com/content/5/1/68
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the human nectin-1 receptor [43]. Nectin-1 is also known
to facilitate virus-induced cell fusion and virus-spread
[44]. Consequently, both OncSyn and OncdSyn viruses
replicated much less efficiently in 4T1 cells than in Vero
cells. In this regard, the limited replication and spread of
these viruses in 4T1 cells would be expected to adversely
affect their oncolytic ability in 4T1-derived tumors in vivo.
Previously, we reported that the OncSyn virus effectively
reduced primary human breast cancer tumors in nude
mice [37]. The disadvantage of the MDA-MB-435S human
breast tumors is that these tumors would be rapidly elim-
inated if they were implanted in immunocompetent mice.
Therefore, we chose the 4T1/Balb/c mouse model system
for additional testing of both the previously constructed
OncSyn virus as well as the newly constructed OncdSyn
virus. Both OncSyn and OncdSyn viruses substantially
reduced the growth of 4T1 tumors compared to the PBS
controls, despite the fact that these viruses did not effi-
ciently replicate in 4T1 cells in cell culture. Apparently,
viral replication and infectious virus production in cell
cultures did not correlate with the oncolytic efficacy of
these viruses, because the OncdSyn virus reduced tumor
volumes equally-well with the OncSyn virus, despite the
fact that OncdSyn replicated approximately less than half
a log than the OncSyn virus in 4T1 cells. Therefore, the rel-
ative increased ability of the OncdSyn virus to destroy
tumors  in vivo must be attributed to its enhanced
fusogenicity.
Multiple murine tumor models have been used as preclin-
ical settings for therapeutic purposes. The 4T1 mammary
carcinoma model has several distinct advantages to be
used as such model. It is regarded as a highly physiologi-
cal, clinically-relevant mouse model that closely resem-
bles stage IV human breast cancer in its properties [40].
4T1 cells are considered to be very weakly immunogenic
(relative antigenic strength is less than 0.01 with 9.9 being
the most immunogenic) [45,46], and they spontaneously
metastasize to distal parts of the body [40,47]. Metastatic
tumor foci in liver and spleen were substantially reduced
in OncSyn and OncdSyn-treated mice in comparison to
PBS-treated control mice. Reduction of metastatic foci in
internal organs (lung, spleen, kidney and liver) was
dependent on the size of the original 4T1 tumor, as well
as the time of necropsy post implantation of tumor cells.
Specifically, there was drastic reduction in tumor foci
detected in lungs when the initial tumor size treated with
the virus was approximately 35–40 mm3 and necropsies
were performed at 33 days after tumor implantation. Fur-
thermore, lungs appeared to have the same number of
metastatic foci with PBS-treated controls when the initial
treated tumors where 80–90 mm3 and necropsies were
performed at day 42 after tumor implantation. This meta-
static pattern revealed that lungs were the primary meta-
static site of the subcutaneous implanted 4T1 cells.
Regardless of the size of the initial tumor treated and the
time of necropsies post tumor implantation, it was evi-
dent that OncSyn and OncdSyn viruses appeared to effi-
ciently reduce the growth of the primary tumor as well as
substantially inhibit or eliminate formation of metastatic
foci.
It is highly likely that reduction of the primary tumor after
oncolytic virotherapy with the OncSyn and OncdSyn
viruses is responsible for the observed reduction in the
formation of secondary tumor foci, since treatment of the
smaller (35–40 mm3) tumors appeared to drastically
reduce lung metastases. Alternatively, it is possible that
anti-tumor immune responses were elicited by exposure
of tumor antigens after destruction of 4T1 cells within the
primary tumor by the OncSyn and OncdSyn viruses. In
this regard, a fusogenic oncolytic HSV-1 Synco-2D was
reported to elicit anti-tumor immune responses when
studied in a similar animal model of mammary carci-
noma utilizing 4T1 cells [14]. A strong T-cell response was
reported also by an HSV-2 derivative oncolytic virus
FusOn-H2 effectively treating primary and metastatic
mammary tumors in vivo [15].
Conclusion
Overall, our results showed that both OncSyn and
OncdSyn viruses can efficiently reduce the primary and
metastatic growth of 4T1 tumors established in immuno-
competent mice. It is expected that these viruses would be
even more efficacious against human breast cancer
tumors by virtue of the fact that they can replicate substan-
tially more efficiently (more than one log) in human than
mouse cells. The availability of both OncSyn and
Table 1: Metastatic nodes in internal organs
Experimental 
groups
No. of mice in 
group
No. of mice with 
metastases in 
internal organs
No. of mice with 
metastases in liver
No. of mice with 
metastases in 
spleen
No. of mice with 
metastases in 
kidney
PBS 9 9673
OncSyn 7 4220
OncdSyn 7 3120
Experimental animals were sacrificed on day 42 post-injection of 4T1 cells and the internal organs were removed and examined for metastases 
formation by gross pathological evaluation as described in Materials and Methods.Virology Journal 2008, 5:68 http://www.virologyj.com/content/5/1/68
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OncdSyn viruses as bacterial artificial chromosomes will
enable the generation of additional recombinant viruses
that carry multiple anti-tumor and immunomodulatory
transgenes, which could further enhance the anti-tumor
efficacy of these viruses.
Materials and methods
Cells
African green monkey kidney (Vero) cells and mouse
mammary tumor cells (4T1) [40] were obtained from the
American Type Culture Collection (Manassas, VA). Vero
cells were maintained in Dulbecco's modified Eagle's
medium (Gibco-BRL; Grand Island, N.Y.), supplemented
with 10% fetal calf serum (FCS) and antibiotics. 4T1 cells
were maintained in RPMI 1640 medium (Hyclone,
Logan, UT) containing 10% FCS. The cultures were main-
tained at 37°C in a humidified atmosphere of 5% CO2/
95% air.
Construction of the doubly fusogenic recombinant virus 
HSV-1 OncdSyn
The previously published OncSyn viral genome recovered
as a bacterial artificial chromosome (bac) into E. coli
(pOncSyn) [37] was used for the construction of pOn-
cdSyn bac plasmid utilizing a new methodology – the
double-red mutagenesis technique in E. coli [39] enabling
the markerless introduction of the gKsyn1 mutation (Ala-
toVal at aa 40). The OncdSyn virus was recovered after
transfection of Vero cells with the pOncdSyn plasmid. The
OncdSyn viral genome and the pOncdSyn bac were exten-
sively characterized by diagnostic PCR and DNA sequenc-
ing to ensure the stability of the viral genomes, the
presence of the parental Onc deletions and the presence of
the gKsyn1 mutation within the gK gene, as described pre-
viously for the OncSyn virus [37].
Phenotypic characterization and replication kinetics of 
the OncSyn and OncdSyn viruses
Cells (both Vero and 4T1) were seeded into 6-well plates
and infected the following day (when they reached
approximately 95% confluency) with the OncSyn or
OncdSyn viruses at a multiplicity of infection (MOI) rang-
ing from 0.001–1 plaque forming units per cell (PFU/
cell). Cells were cultured in a maintenance medium (con-
taining 2% FCS) and were left for 2 days to allow for the
plaques and the cell fusion to develop. Photographs of the
infected cells were taken using a fluorescence microscope.
For assessment of viral plaque morphologies, Vero and
4T1 cells were infected with HSV-1(F), OncSyn or
OncdSyn viruses and visualized after immunohistochem-
istry at 48 hours post-infection (h.p.i.) using horseradish
peroxidase-conjugated anti-HSV antibody (Dako, Carpin-
teri, CA) and Novared substrate development kit (Vector-
Labs, Burlingame, CA).
To determine the replication kinetics of the viruses, one-
step growth kinetics were performed as described previ-
ously [48,49]. Briefly, nearly confluent monolayers of
either Vero or 4T1 cells were infected with each virus at an
MOI of 2 at 4°C for 1 h. Thereafter, virus was allowed to
penetrate for 2 h at 37°C. Any remaining extracellular
virus was inactivated by low-pH treatment with phos-
phate buffered saline at pH 3.0. Cells and supernatants
were harvested immediately thereafter (0 h) or after 12 or
24 h of incubation at 37°C. Virus titers were determined
by endpoint titration of virus stocks on Vero cells.
Animal experiments
Female Balb/c mice were obtained from Harlan (Indiana-
polis, IN) and housed in an animal room which was kept
at 25°C with a 12 hour light-dark cycle. All experimental
Therapeutic effect of OncdSyn virus on lung metastases Figure 6
Therapeutic effect of OncdSyn virus on lung metas-
tases. (a, b) Gross appearance of excised lungs of represent-
ative mice from PBS control and OncdSyn treated groups. (c-
f) Lung tissues were stained with H&E and examined. Repre-
sentative stained sections are shown for PBS (c, d) and 
OncdSyn (e, f) groups at 40× (c, e) and 100× (d, f) magnifica-
tions. Metastatic foci are represented by arrows (c, d).Virology Journal 2008, 5:68 http://www.virologyj.com/content/5/1/68
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procedures involving animals were approved by the insti-
tutional animal care and use committee (IACUC) of the
Louisiana State University. At 6–7 weeks of age the ani-
mals (19–20 g body weight) were implanted subcutane-
ously in the interscapular area with 1 × 105viable 4T1 cells
suspended in 0.2 ml of PBS using a 27 gauge needle. Body
weights were determined weekly, and tumor sizes were
monitored beginning 7 days after tumor inoculation by
direct measuring with a digital microcaliper. Tumor vol-
umes were calculated using the following formula: vol-
ume = (length × width × height)/2. At an average tumor
volume of approximately 80–90 mm3 (first experiment)
or 35–40 mm3 (second experiment), animals were rand-
omized into 3 groups (first experiment) or 2 groups (sec-
ond experiment) using a randomization plan. The groups
of mice received 3 intratumoral injections of the OncSyn,
OncdSyn viral particles, or PBS every four days for the first
experiment and injections of the OncdSyn or PBS every
third day for the second experiment. Each tumor was
injected with approximately 1 × 106 viruses per injection
in 250 μl volume, while control mice received 250 μl of
PBS. Injections were performed slowly at 3 different sites
per tumor. On day 42 for the first experiment and day 33
for the second experiment after initial tumor cell implan-
tation, mice were humanely euthanized in a CO2 chamber
and subjected to gross as well as microscopic histological
examination. Lung and other internal organ metastases
were counted using a dissecting microscope after placing
the resected organs in fixative for 24 hours. The primary
tumor site, lungs, heart, liver, spleen, and kidneys from
each animal were fixed in 10% neutral buffered formalin,
trimmed, paraffin embedded, sectioned, stained with
hematoxylin and eosin (H&E), and evaluated by light
microscopy.
Statistical methods and analyses
The SAS® statistical package (Version 9.1.3) was used for
the analyses of the in vivo studies. Distributions were
examined for normality using the UNIVARIATE procedure
with a Shapiro-Wilk test of normality. For the repeated
measures part of the analyses of tumor volumes and
tumor weights, the GLM procedure was used to conduct a
repeated measures design analyzed as a split-plot arrange-
ment of treatments with TREATMENT (OncSyn,
OncdSyn, and PBS) and MOUSE within TREATMENT as
main plot factors. Subplot factors included PERIOD (days
of measurements) and TREATMENT by PERIOD interac-
tion. When overall analyses determined significance (p =
0.05), Tukey's HSD test was used to examine pairwise dif-
ferences for main effects, and pairwise comparisons of
least square means with regard to interaction effects were
examined with preplanned t-tests. The Wilcoxon Two-
Sample test was used to analyze the difference of lung
metastatic node counts between PBS and OncdSyn
groups.
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